

Edited by Challa Kumar

WILEY-VCH

Biological and Pharmaceutical Nanomaterials



NLS 

Contents

Preface XIV

List of Contributors XVII

I DNA-based Nanomaterials 1

1 Self-assembled DNA Nanotubes 3

Thom LaBean and Sung Ha Park

- 1.1 Introduction 3
- 1.2 DNA Nanotubes Self-assembled from DX Tiles 4
- 1.3 3DAE-E DX Tile Nanotubes 5
- 1.4 DAE-O DX Tile Nanotubes 9
- 1.5 TX Tile Nanotubes 11
- 1.6 4×4 Tile Nanotubes 14
- 1.7 6HB Tile Nanotubes 16
- 1.8 Applications 18
- 1.9 Summary and Perspectives 19
- References 20

2 Nucleic Acid Nanoparticles 23

Guy Zuber, Bénédicte Pons and Andrew W. Fraley

- 2.1 Introduction 23
- 2.2 The Chemical and Physical Properties of Therapeutic DNA 25
- 2.3 Preparation of Nucleic Acid Nanoparticles: Synthesis and Characterization 27
 - 2.3.1 Rationale 27
 - 2.3.2 Synthesis, Characterization and Optimization of Surfactants 31
 - 2.3.3 Organization of the Surfactant–DNA Complexes 35
 - 2.3.4 Quantification of the Stability of Surfactant–DNA Complexes 35
- 2.4 DNA Functionalization for Cell Recognition and Internalization 37
 - 2.4.1 Strategies for Functionalization 37
 - 2.4.2 Intercalation 38
 - 2.4.3 Triple Helix Formation with Oligodeoxyribonucleotides 39

2.4.4	Peptide Nucleic Acids (PNAs)	41
2.4.5	Interactions of DNA with Fusion Proteins	42
2.4.6	Agents that Bind to the Minor Groove	43
2.5	DNA Nanoparticles: Sophistication for Cell Recognition and Internalization	43
2.5.1	Preparation of DNA Nanoparticles Enveloped with a Protective Coat and Cell Internalization Elements	43
2.5.2	Biomedical Application; Cell Targeting and Internalization Properties of Folate-PEG-coated Nanoparticles	46
2.6	Concluding Remarks	46
	References	47
3	Lipoplexes	51
	<i>Sarah Weisman</i>	
3.1	Introduction	51
3.2	DNA Lipoplexes	51
3.2.1	Composition	51
3.2.2	Nanostructure and Microstructure	52
3.2.2.1	Equilibrium Morphology	52
3.2.2.2	Nonequilibrium Morphology	55
3.2.2.3	Lipoplex Size	57
3.2.3	Lipofection Efficiency	57
3.2.3.1	<i>In Vitro</i>	57
3.2.3.2	<i>In Vivo</i>	59
3.3	ODN Lipoplexes	60
3.4	siRNA Lipoplexes	62
	Acknowledgments	62
	References	62
4	DNA-Chitosan Nanoparticles for Gene Therapy: Current Knowledge and Future Trends	68
	<i>Julio C. Fernandes, Marcio José Tiera and Françoise M. Winnik</i>	
4.1	Introduction	68
4.2	Chitosan as a Carrier for Gene Therapy	69
4.2.1	Chitosan Chemistry	69
4.2.2	General Strategies for Chitosan Modification	71
4.2.3	Chitosan-DNA interactions: Transfection Efficacy of Unmodified Chitosan	71
4.3	Modified Chitosans: Strategies to Improve the Transfection Efficacy	79
4.3.1	The Effects of Charge Density/Solubility and Degree of Acetylation	79
4.3.2	Improving the Physicochemical Characteristics of the Nanoparticulate Systems: Solubility, Aggregation and RES Uptake	80

4.3.3	Targeting Mediated by Cell Surface Receptors	81
4.3.4	Hydrophobic Modification: Protecting the DNA and Improving the Internalization Process	83
4.4	Methods of Preparation of Chitosan Nanoparticles	84
4.4.1	Complex Coacervation	84
4.4.2	Crosslinking Methods	86
4.4.2.1	Chemical Crosslinking	86
4.4.2.2	Ionic Crosslinking or Ionic Gelation	86
4.4.2.3	Emulsion Crosslinking	87
4.4.2.4	Spray Drying	88
4.4.2.5	Other Methods	89
4.5	DNA Loading into Nano- and Microparticles of Chitosan	91
4.6	DNA Release and Release Kinetics	93
4.7	Preclinical Evidence of Chitosan–DNA Complex Efficacy	95
4.8	Potential Clinical Applications of Chitosan–DNA in Gene Therapy	97
4.9	Conclusion	99
	Acknowledgments	99
	References	99

II Protein & Peptide-based Nanomaterials 115

5 Plant Protein-based Nanoparticles 117

Anne-Marie Orecchioni, Cécile Duclairoir, Juan Manuel Irache and Evelyne Nakache

5.1	Introduction	117
5.2	Description of Plant Proteins	118
5.2.1	Pea Seed Proteins	119
5.2.2	Wheat Proteins	119
5.3	Preparation of Protein Nanoparticles	120
5.3.1	Preparation of Legumin and Vicilin Nanoparticles	121
5.3.2	Preparation of Gliadin Nanoparticles	122
5.4	Drug Encapsulation in Plant Protein Nanoparticles	124
5.4.1	RA Encapsulation in Gliadin Nanoparticles	124
5.4.2	VE Encapsulation in Gliadin Nanoparticles	125
5.4.3	Lipophilic, Hydrophilic or Amphiphilic Drug Encapsulation	126
5.5	Preparation of Ligand–Gliadin Nanoparticle Conjugates	127
5.6	Bioadhesive Properties of Gliadin Nanoparticles	129
5.6.1	<i>Ex Vivo</i> Studies with Gastrointestinal Mucosal Segments	130
5.6.2	<i>In Vivo</i> Studies with Laboratory Animals	131
5.7	Future Perspectives	135
5.7.1	Size Optimization	135
5.7.2	Immunization in Animals	136
5.8	Conclusion	137
	References	137

6	Peptide Nanoparticles	145
	<i>Klaus Langer</i>	
6.1	Introduction	145
6.2	Starting Materials for the Preparation of Nanoparticles	146
6.3	Preparation Methods	148
6.3.1	Nanoparticle Preparation by Emulsion Techniques	148
6.3.1.1	Emulsion Technique for the Preparation of Albumin-based Microspheres and Nanoparticles	148
6.3.1.2	Emulsion Technique for the Preparation of Gelatin-based Microspheres and Nanoparticles	151
6.3.1.3	Emulsion Technique for the Preparation of Casein-based Microspheres and Nanoparticles	153
6.3.2	Nanoparticle Preparation by Coacervation	154
6.3.2.1	Complex Coacervation Techniques for the Preparation of Nanoparticles	154
6.3.2.2	Simple Coacervation (Desolvation) Techniques for the Preparation of Nanoparticles	155
6.4	Basic Characterization Techniques for Peptide Nanoparticles	159
6.5	Drug Targeting with Nanoparticles	161
6.5.1	Passive Drug Targeting with Particle Systems	163
6.5.2	Active Drug Targeting with Particle Systems	163
6.5.3	Surface Modifications of Protein-based Nanoparticles	164
6.5.4	Surface Modification by Different Hydrophilic Compounds	164
6.5.5	Surface Modification by Polyethylene Glycol (PEG) Derivatives	165
6.5.6	Surface Modification by Drug-targeting Ligands	166
6.5.7	Different Surface Modification Strategies	168
6.6	Applications as Drug Carriers and for Diagnostic Purposes	169
6.6.1	Protein-based Nanoparticles in Gene Therapy	170
6.6.2	Parenteral Application Route	172
6.6.2.1	Preclinical Studies with Protein-based Particles	172
6.6.2.2	Clinical Studies with Protein-based Particles	172
6.6.3	Topical Application of Protein-based Particles	174
6.6.4	Peroral Application of Protein-based Particles	175
6.7	Immunological Reactions with Protein-based Microspheres	175
6.8	Concluding Remarks	176
	References	176
7	Albumin Nanoparticles	185
	<i>Juan Manuel Irache and Socorro Espuelas</i>	
7.1	Introduction	185
7.2	Serum Albumin	186
7.3	Preparation of Albumin Nanoparticles	187
7.3.1	“Conventional” Albumin Nanoparticles	188
7.3.1.1	Preparation of Albumin Nanoparticles by Desolvation or Coacervation	189

7.3.1.2	Preparation of Albumin Nanoparticles by Emulsification	192
7.3.1.3	Other Techniques to Prepare Albumin Nanoparticles	193
7.3.2	Surface-modified Albumin Nanoparticles	193
7.3.3	Drug Encapsulation in Albumin Nanoparticles	194
7.4	Biodistribution of Albumin Nanoparticles	196
7.5	Pharmaceutical Applications	198
7.5.1	Albumin Nanoparticles for Diagnostic Purposes	198
7.5.1.1	Radiopharmaceuticals	198
7.5.1.2	Echo-contrast Agents	199
7.5.2	Albumin Nanoparticles as Carriers for Oligonucleotides and DNA	199
7.5.3	Albumin Nanoparticles in the Treatment of Cancer	201
7.5.3.1	Fluorouracil and Methotrexate Delivery	201
7.5.3.2	Paclitaxel Delivery	202
7.5.3.3	Albumin Nanoparticles in Suicide Gene Therapy	203
7.5.4	Magnetic Albumin Nanoparticles	204
7.5.5	Albumin Nanoparticles for Ocular Drug Delivery	205
7.5.5.1	Topical Drug Delivery	205
7.5.5.2	Intravitreal Drug Delivery	205
7.6	Concluding Remarks	207
	References	208
8	Nanoscale Patterning of S-Layer Proteins as a Natural Self-assembly System	219
	<i>Margit Sára, D. Pum, C. Huber, N. Ilk, M. Pleschberger and U. B. Sleytr</i>	
8.1	Introduction	219
8.2	General Properties of S-Layers	220
8.2.1	Structure, Isolation, Self-Assembly and Recrystallization	220
8.2.2	Chemistry and Molecular Biology	221
8.2.3	S-Layers as Carbohydrate-binding Proteins	223
8.3	Nanoscale Patterning of S-Layer Proteins	224
8.3.1	Properties of S-Layer Proteins Relevant for Nanoscale Patterning	224
8.3.2	Immobilization of Functionalities by Chemical Methods	225
8.3.3	Patterning by Genetic Approaches	226
8.3.3.1	The S-Layer Proteins SbsA, SbsB and SbsC	226
8.3.3.2	S-Layer Fusion Proteins	228
8.4	Spatial Control over S-Layer Reassembly	241
8.5	S-Layers as Templates for the Formation of Regularly Arranged Nanoparticles	242
8.5.1	Binding of Molecules and Nanoparticles to Functional Domains	242
8.5.2	<i>In Situ</i> Synthesis of Nanoparticles on S-Layers	244
8.6	Conclusions and Outlook	244
	Acknowledgments	245
	References	245

III	Pharmaceutically Important Nanomaterials	253
9	Methods of Preparation of Drug Nanoparticles	255
	<i>Jonghwi Lee, Gio-Bin Lim and Hesson Chung</i>	
9.1	Introduction	255
9.2	Structures of Drug Nanoparticles	257
9.3	Thermodynamic Approaches	257
9.3.1	Lipid-based Pharmaceutical Nanoparticles	258
9.3.2	What is a Lipid?	259
9.3.3	Liquid Crystalline Phases of Hydrated Lipids with Planar and Curved Interfaces	260
9.3.4	Oil-in-water-type Lipid Emulsion	261
9.3.5	Liposomes	261
9.3.6	Cubosomes and Hexosomes	262
9.3.7	Other Lipid-based Pharmaceutical Nanoparticles	263
9.4	Mechanical Approaches	264
9.4.1	Types of Processing	264
9.4.2	Characteristics of Wet Comminution	266
9.4.3	Drying of Liquid Nanodispersions	267
9.5	SCF Approaches	270
9.5.1	SCF Characteristics	270
9.5.2	Classification of SCF Particle Formation Processes	271
9.5.3	RESS	272
9.5.4	SAS	273
9.5.5	SEDS	274
9.6	Electrostatic Approaches	275
9.6.1	Electrical Potential and Interfaces	275
9.6.2	Electrospraying	277
	References	280
10	Production of Biofunctionalized Solid Lipid Nanoparticles for Site-specific Drug Delivery	287
	<i>Rainer H. Müller, Eliana B. Souto, Torsten Göppert and Sven Gohla</i>	
10.1	Introduction	287
10.2	Concept of Differential Adsorption	289
10.3	Production of SLN	292
10.4	Functionalization by Surface Modification	294
10.5	Conclusions	298
	References	299
11	Biocompatible Nanoparticulate Systems for Tumor Diagnosis and Therapy	304
	<i>Mostafa Sadoqi, Sunil Kumar, Cesar Lau-Cam and Vishal Saxena</i>	
11.1	Introduction	304

11.2	Nanoscale Particulate Systems and their Building Blocks/ Components	305
11.2.1	Dendrimers	305
11.2.2	Buckyballs and Buckytubes	307
11.2.3	Quantum Dots	309
11.2.4	Polymeric Micelles	310
11.2.5	Liposomes	310
11.3	Biodegradable Nanoparticles	312
11.3.1	Preparation of Nanoparticles	313
11.4	Biodegradable Optical Nanoparticles	314
11.4.1	Optical Nanoparticles as a Potential Technology for Tumor Diagnosis	314
11.4.2	Optical Nanoparticles as a Potential Technology for Tumor Treatment	315
11.5	Optical Imaging and PDT	317
11.5.1	Optical Imaging	317
11.5.1.1	Fluorescence-based Optical Imaging	317
11.5.1.2	NIR Fluorescence Imaging	317
11.5.1.3	NIR Dyes for Fluorescence Imaging	318
11.5.2	PDT	318
11.5.2.1	Basis of PDT	319
11.5.2.2	Photosensitizers for PDT	320
11.5.3	ICG: An Ideal Photoactive Agent for Tumor Diagnosis and Treatment	320
11.5.3.1	Clinical Uses of ICG	320
11.5.3.2	Structure and Physicochemical Properties of ICG	321
11.5.3.3	Binding Properties of ICG	321
11.5.3.4	Metabolism, Excretion and Pharmacokinetics of ICG	322
11.5.3.5	Toxicity of ICG	322
11.5.3.6	Tumor Imaging with ICG	322
11.5.3.7	PDT with ICG	323
11.5.3.8	Limitations of ICG for Tumor Diagnosis and Treatment	324
11.5.3.9	Recent Approaches for Improving the Blood Circulation Time and Uptake of ICG by Tumors	325
11.5.3.10	Recent Approaches for ICG Stabilization <i>In Vitro</i>	326
11.6	PLGA-based Nanoparticulate Delivery System for ICG	327
11.6.1	Rationale of Using a PLGA-based Nanoparticulate Delivery System for ICG	327
11.6.2	<i>In Vivo</i> Pharmacokinetics of ICG Solutions and Nanoparticles	331
11.7	Conclusions and Future Work	336
	References	338
12	Nanoparticles for Crossing Biological Membranes	349
	<i>R. Pawar, A. Avramoff and A. J. Domb</i>	
12.1	Introduction	349

12.2	Cell Membranes	350
12.2.1	Functions of Biological Membranes	351
12.2.2	Kinetic and Thermodynamic Aspects of Biological Membranes	352
12.3	Problems of Drugs Crossing through Biological Membranes	354
12.3.1	Through the Skin	354
12.3.1.1	Mechanical Irritation of Skin	355
12.3.1.2	Low-voltage Electroporation of the Skin	355
12.3.2	Through the BBB	357
12.3.2.1	Small Drugs	359
12.3.2.1.1	Limitations of Small Drugs	359
12.3.2.2	Peptide Drug Delivery via SynB Vectors	360
12.3.3	GI Barrier	360
12.3.3.1	Intestinal Translocation and Disease	361
12.4	Nanoparticulate Drug Delivery	362
12.4.1	Skin	363
12.4.1.1	Skin as Semipermeable Nanoporous Barrier	363
12.4.1.2	Hydrophilic Pathway through the Skin Barrier	363
12.4.2	Solid-Lipid Nanoparticles (SLN) Skin Delivery	364
12.4.2.1	Chemical Stability of SLN	364
12.4.2.2	<i>In Vitro</i> Occlusion of SLN	365
12.4.2.3	<i>In Vivo</i> SLN: Occlusion, Elasticity and Wrinkles	365
12.4.2.4	Active Compound Penetration into the Skin	365
12.4.2.5	Controlled Release of Cosmetic Compounds	365
12.4.2.6	Novel UV Sunscreen System Using SLN	366
12.4.3	Polymer-based Nanoparticulate Delivery to the Skin	366
12.4.4	Subcutaneous Nanoparticulate Antiepileptic Drug Delivery	366
12.4.5	Nanoparticulate Anticancer Drug Delivery	367
12.4.5.1	Paclitaxel	368
12.4.5.2	Doxorubicin	368
12.4.5.3	5-Fluorouracil (5-FU)	369
12.4.5.4	Antineoplastic Agents	369
12.4.5.5	Gene Delivery	369
12.4.5.6	Breast Cancer	370
12.4.6	Nanofibers Composed of Nonbiodegradable Polymer	370
12.4.6.1	Electrostatic Spinning	371
12.4.6.2	Scanning Electron Microscopy	371
12.4.6.3	Differential Scanning Calorimetry (DSC)	371
12.5	Nanoparticulate Delivery to the BBB	371
12.5.1	Peptide Delivery to the BBB	372
12.5.1.1	Peptide Conjugation through a Disulfide Bond	373
12.5.2	Biodegradable Polymer Based Nanoparticulate Delivery to BBB	373
12.5.3	Nanoparticulate Gene Delivery to the BBB	374
12.5.4	Mechanism of Nanoparticulate Drug Delivery to the BBB	375
12.5.5	Nanoparticulate Thiamine-coated Delivery to the BBB	376
12.5.6	Nanoparticle Optics and Living Cell Imaging	376

12.6	Oral Nanoparticulate Delivery	378
12.6.1	Lectin-conjugated Nanoparticulate Oral Delivery	379
12.6.2	Oral Peptide Nanoparticulate-based Delivery	380
12.6.3	Polymer-Based Oral Peptide Nanoparticulate Delivery	381
12.6.3.1	Polyacrylamide Nanospheres	381
12.6.3.2	Poly(alkyl cyanoacrylate) PACA Nanocapsules	381
12.6.3.3	Derivatized Amino Acid Microspheres	382
12.6.4	Lymphatic Oral Nanoparticulate Delivery	382
12.6.5	Oral Nanosuspension Delivery	383
12.6.6	Mucoadhesion of Nanoparticles after Oral Administration	384
12.6.7	Protein Nanoparticulate Oral Delivery	384
	References	385
	Index	394